Generic Medicine Info
Indications and Dosage
Neonatal respiratory distress syndrome
Child: Premature neonates (<29 weeks gestation) at significant risk for respiratory distress syndrome (RDS): As prophylaxis: 3 mL/kg given as soon as possible, preferably within 30 minutes of birth. Neonates (≤72 hours) with confirmed RDS and requiring endotracheal intubation: As treatment: 3 mL/kg as soon as diagnosis is confirmed. Doses may be repeated 12 hourly for up to a total of 3 doses.
Special Precautions
Not indicated as a substitute for neonatal intensive care. Neonates.
Adverse Reactions
Significant: Airway obstruction, cyanosis, bradycardia, drug reflux into the endotracheal tube; intraventricular haemorrhage, periventricular leucomalacia.
Surgical and medical procedures: Requirement for manual ventilation, reintubation.
Monitoring Parameters
Monitor heart rate and transcutaneous oxygen saturation during administration. Perform frequent arterial blood gas sampling after the initial dose.
Mechanism of Action: Calfactant is an extract of natural surfactant obtained from calf lungs which include phospholipids, neutral lipids, and hydrophobic surfactant-associated proteins B and C. It acts similarly to endogenous lung surfactant by rapidly adsorbing to the surface of the air:liquid interface and modifying the surface tension. It stabilises the alveoli by modifying alveolar surface tension.
Store upright, between 2-8°C. Do not freeze. Do not shake. Protect from light.
MIMS Class
Other Drugs Acting on the Respiratory System
Onrust SV, Dooley M, Goa KL. Calfactant: A Review of its Use in Neonatal Respiratory Distress Syndrome. Adis International Limited, Auckland, New Zealand. 1999 Jul;1(3):219-243. doi: 10.2165/00128072-199901030-00006. Accessed 06/07/2022. PMID: 10937453

Anon. Calfactant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 06/07/2022.

Buckingham R (ed). Pulmonary Surfactants. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 06/07/2022.

Infasurf Intratracheal Suspension (Transmedic Healthcare Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 06/07/2022.

Infasurf Suspension (ONY Biotech Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 06/07/2022.

Disclaimer: This information is independently developed by MIMS based on Calfactant from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in